We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Published Online:https://doi.org/10.2217/rme.10.82

Dr Roger A Barker is a University Reader in Clinical Neuroscience and Honorary Consultant in Neurology at the Addenbrooke’s Hospital. He trained at Oxford and in London and has been in his current position for 10 years, having completed an MRC Clinician Scientist Fellowship prior to this. His main interests are in the neurodegenerative disorders of the nervous system, in particular Parkinson’s disease and Huntington’s disease. Dr Barker combines basic research investigating cell therapies to treat these conditions, with clinically based work on defining the natural history and heterogeneity of both diseases. He is a member of the CURE PD Research Advisory Panel and the MRC Stem Cell Liaison Committee. He is a member of the Regenerative Medicine editorial board and co-editor-in-chief of the journals ACNR and the Journal of Neurology.

References

  • Freed CR, Greene PE, Breeze RE et al.: Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N. Engl. J. Med.344(10),710–719 (2001).
  • Ma Y, Tang C, Chaly T et al.: Dopamine cell implantation in Parkinson’s disease: long-term clinical and 18F-FDOPA PET outcomes. J. Nucl. Med.51(1),7–15 (2010).